Highlights

  • Fisher & Paykel Healthcare Corporation Limited (ASX:FPH) was trading at AUD 34.79, down 1.08% at the time of writing on 18 August 2026.
  • The company develops and manufactures respiratory and acute care medical devices used in hospitals and homecare settings globally.
  • Fisher & Paykel Healthcare reported FY26 Operating Revenue of NZD 1.95 billion, up 12% compared with FY25, with operating profit of NZD 491.1 million.
  • The S&P/ASX 200 Health Care (ASX:XHJ) was trading at 30,834.80 points, up 7.92% (+2,262.60) today.

Fisher & Paykel Healthcare Corporation Limited (ASX:FPH) was trading at AUD 34.79, down 1.08% at the time of writing on 18 August 2026. The company’s share price movement comes as investors continue to assess its respiratory care business, medical device Demand and global healthcare market conditions.

The broader Australian market was trading in positive territory, with the S&P/ASX 200 (ASX:XJO) at 9,085.20 points, up 0.13% (+12.00) today. The S&P/ASX 300 (ASX:XKO) was trading at 9,022.40 points, up 0.16% (+14.20) today. Within healthcare, the S&P/ASX 200 Health Care (ASX:XHJ) was trading at 30,834.80 points, up 7.92% (+2,262.60) today.

Daily share price movements can reflect investor sentiment, sector trends, trading activity and broader market conditions. However, a single session’s movement does not necessarily indicate a change in a company’s financial performance, operating position or long-term outlook.

Investors generally monitor medical device companies through revenue growth, product adoption, healthcare spending trends, regulatory approvals, Research and Development activities and international market performance.

Respiratory care Business and global operations

Fisher & Paykel Healthcare is a New Zealand-based medical device company focused on respiratory and acute care products. The company designs, manufactures and markets products used in respiratory support, including systems for nasal high flow therapy, continuous positive airway pressure (CPAP), non-invasive ventilation and invasive ventilation.

The company supplies healthcare providers, hospitals and homecare patients across international markets. Its products are used in areas including respiratory care, sleep apnea treatment and critical care environments.

Fisher & Paykel Healthcare’s business model is centred around product innovation, Manufacturing capability, global distribution and ongoing Investment in healthcare technology. The company operates in markets influenced by ageing populations, respiratory disease prevalence, hospital infrastructure investment and healthcare system requirements.

Medical device companies are generally assessed through factors such as product portfolio performance, research and development pipelines, regulatory approvals and the ability to expand across healthcare markets.

Latest update and FY26 financial performance

Fisher & Paykel Healthcare released its FY26 full-year results on 27 May 2026, reporting record operating revenue of NZD 1.95 billion, up 12% compared with FY25. The company reported operating profit of NZD 491.1 million, up 13%, while net profit after tax reached NZD 352.7 million, up 17% compared with the prior year.

The company reported that hospital product revenue increased 14% to NZD 1.54 billion, while homecare product revenue increased 5% to NZD 412.2 million. Within hospital products, respiratory and acute care products continued to represent the majority of revenue.

Fisher & Paykel Healthcare reported that its largest markets included the United States, Europe, New Zealand and Australia. The company continued to invest in research and development, manufacturing capacity and global commercial activities.

The company also announced a final Dividend of NZD 0.25 per share, bringing total FY26 dividends to NZD 0.45 per share.

The FY26 update highlighted continued demand for respiratory care products while also outlining ongoing investment in innovation, manufacturing and market expansion.

Product innovation and healthcare market position

Product development remains a central part of Fisher & Paykel Healthcare’s strategy. The company continues to invest in respiratory technologies designed for hospital and homecare environments.

The respiratory care market is influenced by several long-term healthcare trends, including increasing demand for respiratory support equipment, ageing populations and continued focus on hospital efficiency.

The company’s hospital business remains an important contributor, with products used across intensive care units, emergency departments and general hospital environments. Homecare products, including sleep apnea-related therapies, provide exposure to longer-term patient care markets.

Investors generally monitor product launches, regulatory approvals and adoption rates as indicators of future market opportunities.

Manufacturing capacity is also an important consideration for medical device companies. Fisher & Paykel Healthcare operates manufacturing facilities and continues to invest in production capability to support global demand.

The company’s international exposure provides access to multiple healthcare markets but also creates exposure to currency movements, regulatory environments and regional healthcare spending patterns.

Factors investors monitor for Fisher & Paykel Healthcare

Medical device companies operate within highly regulated healthcare markets. Investors generally monitor product demand, regulatory requirements, healthcare funding, competitive developments and research outcomes.

For Fisher & Paykel Healthcare, hospital product performance remains a key area of focus. Investors typically assess whether demand for respiratory devices continues across major healthcare markets.

Currency movements are another consideration due to the company’s global operations and international revenue exposure. Changes in exchange rates can influence reported financial outcomes.

Research and development investment also remains important. Medical device companies generally need ongoing innovation to maintain product competitiveness and address changing healthcare requirements.

The company’s manufacturing operations and Supply chain management are additional areas investors monitor, particularly as global healthcare demand changes.

A daily share price decline does not independently confirm weaker company fundamentals. Investors generally review financial results, operational performance, product developments and broader healthcare sector conditions.

Healthcare sector outlook and future considerations

The healthcare sector continues to evolve through technological innovation, changing patient needs and increasing demand for specialised medical products.

For Fisher & Paykel Healthcare, future investor attention is likely to remain on respiratory product demand, hospital market trends, homecare opportunities, research and development activities and international expansion.

The company’s share price was trading at AUD 34.79, down 1.08% at the time of writing on 18 August 2026. While daily movements reflect short-term market activity, broader company assessment generally involves reviewing financial performance, product portfolio strength and healthcare market trends.

Conclusion

Fisher & Paykel Healthcare (ASX:FPH) continues to operate as a global respiratory and acute care medical device company with exposure to hospital and homecare markets. The company’s share price was trading at AUD 34.79, down 1.08% at the time of writing on 18 August 2026. Daily price movements provide insight into market activity, while investors generally monitor revenue growth, product innovation, healthcare demand and operational execution.